Pertussis-Specific Memory B-Cell and Humoral IgG Responses in Adolescents after a Fifth Consecutive Dose of Acellular Pertussis Vaccine

Abstract

In order to impede the increase in pertussis incidence in the adolescent group, a school-leaving booster dose administered at the age of 14 to 16 years will be introduced in Sweden in 2016. Preceding this introduction, an open-label, randomized, multicenter, clinical trial without a control group and with blinded analysis was performed, investigating both safety and immunogenicity. Reported here are the memory B-cell and serological responses detected in a smaller cohort (n ‫؍‬ 34) of the 230 subjects recruited to the study. All subjects had received primary vaccination consisting of three doses of diphtheria-tetanus-5-component pertussis (DTaP5) vaccine, at 3, 5, and 12 months of age, and a tetanus-low-dose diphtheria-5-component pertussis (Tdap5) vaccine booster at 5.5 years. In this study, the subjects were randomly assigned and received either a Tdap1 or Tdap5 booster. Of the 230 participants, 34 subjects had samples available for evaluation of IgG-producing memory B-cell responses. Both vaccine groups had significant increases in pertussis toxin-specific serum IgG levels, but only the 1-component group showed significant increases in pertussis toxin-specific memory B cells. The 5-component group had significant increases in filamentous hemagglutinin-and pertactin-specific memory B-cell and serum IgG levels; these were not seen in the 1-component group, as expected. In conclusion, this study shows that a 5th consecutive dose of an acellular pertussis vaccine induces B-cell responses in vaccinated adolescents. (This study has been registered at EudraCT under registration no. 2008-008195-13 and at ClinicalTrials.gov under registration no. NCT00870350.)

Live attenuated pertussis vaccine BPZE1 induces a broad antibody response in humans

“…Peripheral venous blood was collected in BD Vacutainer CPT tubes at the day prior to vaccination and at days 4, 14, and 28, and months 6 and 12 after vaccination, followed by PBMCs isolation and serum collection. The Tdap vaccine study is a randomized, multicenter study in which the immunogenicity and safety of the tetanus, diphtheria, and acellular pertussis vaccine booster were evaluated (72,73). In part of this clinical trial, adolescents (14-15 years of age) with a vaccination history of 3 primary immunizations of DTaP5 (Connaught HCP4DT) at 3, 5, and 12 months of age plus a booster immunization of Tdap5 (Triaxis, Sanofi Pasteur) at 5.5 years of age received another booster dose of Tdap5 (Triaxis, Sanofi Pasteur).…”

Humoral and cell mediated immune responses to a pertussis containing vaccine in pregnant and nonpregnant women

“…For one, protection against pertussis is dependent both on antibody-and cell-mediated immune (CMI) responses [16]. Vaccination induces these pertussisspecific CMI responses in infants [17], adolescents [18][19][20], and adults [21,22] but CMI responses to pertussis vaccination during pregnancy have so far not been reported. In a number of papers reported on maternal vaccination (for a more recent review [23]), focus has been so far on the induction of antibodies.…”

Immunogenity and antibodies persistance of diphteria-tetanus-acellular pertussis vaccination in adolescent and adults: a sistematic review of the literature showed different response to the available vaccines

“…Jahnmatz et al [ 16 ] described a study on 230 adolescents (aged 14-15 years) in an open-label, randomized multicenter study without a control group and with blinded analysis. Both vaccine groups had significant increases in Bordetella pertussis toxin-specific serum IgG levels, and the 5-component group had significant increases in filamentous hemagglutinin- and pertactin-specific memory B-cell and serum IgG levels; these were not seen in the 1-component group, as expected.…”